{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:02:04Z","timestamp":1790661724774,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01462-8","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:25:07Z","timestamp":1790659507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Update of Oxidative Stress in Atherosclerosis with Emphasis on the LOX-1\u2013NLRP3 Inflammasome Axis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-1626","authenticated-orcid":false,"given":"Keshav","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawahar L.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"1462_CR1","doi-asserted-by":"publisher","unstructured":"Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative Stress in Atherosclerosis. Curr Atheroscler Rep. 2017;19:42. https:\/\/doi.org\/10.1007\/s11883-017-0678-6","DOI":"10.1007\/s11883-017-0678-6"},{"key":"1462_CR2","doi-asserted-by":"publisher","unstructured":"Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204\u201312. https:\/\/doi.org\/10.1038\/ni.2001","DOI":"10.1038\/ni.2001"},{"key":"1462_CR3","doi-asserted-by":"publisher","unstructured":"3. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868\u201374. https:\/\/doi.org\/10.1038\/nature01323","DOI":"10.1038\/nature01323"},{"key":"1462_CR4","doi-asserted-by":"publisher","unstructured":"Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. London, England; 2023;401:1293\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(23)00215-5","DOI":"10.1016\/S0140-6736(23)00215-5"},{"key":"1462_CR5","doi-asserted-by":"publisher","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914","DOI":"10.1056\/NEJMoa1707914"},{"key":"1462_CR6","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med"},{"key":"1462_CR7","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2021372.","journal-title":"N Engl J Med"},{"key":"1462_CR8","unstructured":"Lodoco (colchicine) tablets."},{"key":"1462_CR9","doi-asserted-by":"publisher","unstructured":"Pothineni NVK, Karathanasis SK, Ding Z, Arulandu A, Varughese KI, Mehta JL. LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation. J Am Coll Cardiol. 2017;69:2759\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.010","DOI":"10.1016\/j.jacc.2017.04.010"},{"key":"1462_CR10","doi-asserted-by":"publisher","unstructured":"Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res. 2007;100:1634\u201342. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.149724","DOI":"10.1161\/CIRCRESAHA.107.149724"},{"key":"1462_CR11","doi-asserted-by":"publisher","unstructured":"Ding Z, Liu S, Wang X, Theus S, Fan Y, Deng X, et al. LOX-1 - dependent mitochondrial DNA damage and NLRP3 activation during systemic inflammation in mice. Biochem Biophys Res Commun. 2014;451:637\u201343. https:\/\/doi.org\/10.1016\/j.bbrc.2014.08.034","DOI":"10.1016\/j.bbrc.2014.08.034"},{"key":"1462_CR12","doi-asserted-by":"publisher","unstructured":"Ding Z, Liu S, Wang X, Dai Y, Khaidakov M, Deng X, et al. LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis. Cardiovasc Res. 2014;103:619\u201328. https:\/\/doi.org\/10.1093\/cvr\/cvu114","DOI":"10.1093\/cvr\/cvu114"},{"key":"1462_CR13","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1038\/s41591-025-03951-w","volume":"31","author":"ML O\u2019Donoghue","year":"2025","unstructured":"O\u2019Donoghue ML, Morrow DA, Vavere AL, Kardassis D, Moura FA, Fagundes AADP, et al. Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial. Nat Med. 2025;31:3553\u20139. https:\/\/doi.org\/10.1038\/s41591-025-03951-w.","journal-title":"Nat Med"},{"key":"1462_CR14","doi-asserted-by":"publisher","unstructured":"Zhang J, Yu L, Yang W, Cao L, Wang X, Kao C, et al. Macrophage-Specific E3 Ubiquitin Ligase TRIM31 Reduces Atherosclerotic Plaque Formation by Targeting LOX-1. Circulation. 2026;153:576\u201396. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.076514","DOI":"10.1161\/CIRCULATIONAHA.125.076514"},{"key":"1462_CR15","doi-asserted-by":"publisher","unstructured":"F\u00f6rstermann U, Xia N, Li H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circ Res. 2017;120:713\u201335. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.309326","DOI":"10.1161\/CIRCRESAHA.116.309326"},{"key":"1462_CR16","doi-asserted-by":"publisher","unstructured":"Judkins CP, Diep H, Broughton BRS, Mast AE, Hooker EU, Miller AA, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-\/- mice. Am J Physiol Heart Circ Physiol. 2010;298:H24-32. https:\/\/doi.org\/10.1152\/ajpheart.00799.2009","DOI":"10.1152\/ajpheart.00799.2009"},{"key":"1462_CR17","doi-asserted-by":"publisher","unstructured":"Konior A, Schramm A, Czesnikiewicz-Guzik M, Guzik TJ. NADPH Oxidases in Vascular Pathology. Antioxid Redox Signal. 2014;20:2794\u2013814. https:\/\/doi.org\/10.1089\/ars.2013.5607","DOI":"10.1089\/ars.2013.5607"},{"key":"1462_CR18","doi-asserted-by":"publisher","unstructured":"Schr\u00f6der K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res. 2012;110:1217\u201325. https:\/\/doi.org\/10.1161\/CIRCRESAHA.112.267054","DOI":"10.1161\/CIRCRESAHA.112.267054"},{"key":"1462_CR19","doi-asserted-by":"publisher","unstructured":"Sch\u00fcrmann C, Rezende F, Kruse C, Yasar Y, L\u00f6we O, Fork C, et al. The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur Heart J. 2015;36:3447\u201356. https:\/\/doi.org\/10.1093\/eurheartj\/ehv460","DOI":"10.1093\/eurheartj\/ehv460"},{"key":"1462_CR20","doi-asserted-by":"publisher","unstructured":"Craige SM, Kant S, Reif M, Chen K, Pei Y, Angoff R, et al. Endothelial NADPH oxidase 4 protects ApoE-\/- mice from atherosclerotic lesions. Free Radic Biol Med. 2015;89:1\u20137. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.07.004","DOI":"10.1016\/j.freeradbiomed.2015.07.004"},{"key":"1462_CR21","doi-asserted-by":"publisher","unstructured":"Vendrov AE, Lozhkin A, Hayami T, Levin J, Silveira Fernandes Chamon J, Abdel-Latif A, et al. Mitochondrial dysfunction and metabolic reprogramming induce macrophage pro-inflammatory phenotype switch and atherosclerosis progression in aging. Front Immunol. 2024;15:1410832. https:\/\/doi.org\/10.3389\/fimmu.2024.1410832","DOI":"10.3389\/fimmu.2024.1410832"},{"key":"1462_CR22","doi-asserted-by":"publisher","unstructured":"Marqu\u00e9s J, Cort\u00e9s A, Pejenaute \u00c1, Zalba G. Implications of NADPH oxidase 5 in vascular diseases. Int J Biochem Cell Biol. 2020;128:105851. https:\/\/doi.org\/10.1016\/j.biocel.2020.105851","DOI":"10.1016\/j.biocel.2020.105851"},{"key":"1462_CR23","doi-asserted-by":"publisher","unstructured":"Manea A, Manea S-A, Gan AM, Constantin A, Fenyo IM, Raicu M, et al. Human monocytes and macrophages express NADPH oxidase 5; a potential source of reactive oxygen species in atherosclerosis. Biochem Biophys Res Commun. 2015;461:172\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2015.04.021","DOI":"10.1016\/j.bbrc.2015.04.021"},{"key":"1462_CR24","doi-asserted-by":"publisher","unstructured":"da Silva JF, Alves JV, Silva-Neto JA, Costa RM, Neves KB, Alves-Lopes R, et al. Lysophosphatidylcholine induces oxidative stress in human endothelial cells via NOX5 activation - implications in atherosclerosis. Clin Sci. London, England : 1979; 2021;135:1845\u201358. https:\/\/doi.org\/10.1042\/CS20210468","DOI":"10.1042\/CS20210468"},{"key":"1462_CR25","doi-asserted-by":"publisher","unstructured":"Vlad M-L, Manea S-A, Lazar A-G, Raicu M, Muresian H, Simionescu M, et al. Histone Acetyltransferase-Dependent Pathways Mediate Upregulation of NADPH Oxidase 5 in Human Macrophages under Inflammatory Conditions: A Potential Mechanism of Reactive Oxygen Species Overproduction in Atherosclerosis. Oxid Med Cell Longev. 2019;2019:3201062. https:\/\/doi.org\/10.1155\/2019\/3201062","DOI":"10.1155\/2019\/3201062"},{"key":"1462_CR26","doi-asserted-by":"publisher","first-page":"C749","DOI":"10.1152\/ajpcell.00346.2016","volume":"312","author":"Y-M Kim","year":"2017","unstructured":"Kim Y-M, Kim S-J, Tatsunami R, Yamamura H, Fukai T, Ushio-Fukai M. ROS-induced ROS release orchestrated by Nox4, Nox2, and mitochondria in VEGF signaling and angiogenesis. Am J Physiol Cell Physiol. 2017;312:C749-64. https:\/\/doi.org\/10.1152\/ajpcell.00346.2016.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1462_CR27","doi-asserted-by":"publisher","unstructured":"Wiley CD, Velarde MC, Lecot P, Liu S, Sarnoski EA, Freund A, et al. Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype. Cell Metab. 2016;23:303\u201314. https:\/\/doi.org\/10.1016\/j.cmet.2015.11.011","DOI":"10.1016\/j.cmet.2015.11.011"},{"key":"1462_CR28","doi-asserted-by":"publisher","unstructured":"Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401\u201314. https:\/\/doi.org\/10.1016\/j.immuni.2012.01.009","DOI":"10.1016\/j.immuni.2012.01.009"},{"key":"1462_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-018-0372-z","volume":"560","author":"Z Zhong","year":"2018","unstructured":"Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin X-J, et al. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature. 2018;560:198\u2013203. https:\/\/doi.org\/10.1038\/s41586-018-0372-z.","journal-title":"Nature"},{"key":"1462_CR30","doi-asserted-by":"publisher","unstructured":"Khetarpal SA, Qamar A, Bick AG, Fuster JJ, Kathiresan S, Jaiswal S, et al. Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74:578\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.045","DOI":"10.1016\/j.jacc.2019.05.045"},{"key":"1462_CR31","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1161\/CIRCULATIONAHA.123.065344","volume":"148","author":"M Yalcinkaya","year":"2023","unstructured":"Yalcinkaya M, Liu W, Thomas L-A, Olszewska M, Xiao T, Abramowicz S, et al. BRCC3-mediated NLRP3 deubiquitylation promotes inflammasome activation and atherosclerosis in Tet2 clonal hematopoiesis. Circulation. 2023;148:1764\u201377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065344.","journal-title":"Circulation"},{"key":"1462_CR32","doi-asserted-by":"publisher","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. New York, N.Y.; 2017;355:842\u20137. https:\/\/doi.org\/10.1126\/science.aag1381","DOI":"10.1126\/science.aag1381"},{"key":"1462_CR33","doi-asserted-by":"publisher","unstructured":"Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, et al. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. JAMA Cardiol. 2022;7:521\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2022.0386","DOI":"10.1001\/jamacardio.2022.0386"},{"key":"1462_CR34","doi-asserted-by":"publisher","unstructured":"M\u00fcnzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC. Impact of Oxidative Stress on the Heart and Vasculature Part 2 of a 3-Part Series. J Am Coll Cardiol. 2017;70:212\u201329. https:\/\/doi.org\/10.1016\/j.jacc.2017.05.035","DOI":"10.1016\/j.jacc.2017.05.035"},{"key":"1462_CR35","doi-asserted-by":"publisher","unstructured":"He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2017;44:532\u201353. https:\/\/doi.org\/10.1159\/000485089","DOI":"10.1159\/000485089"},{"key":"1462_CR36","doi-asserted-by":"publisher","unstructured":"Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. London, England; 2003;361:2017\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(03)13637-9","DOI":"10.1016\/S0140-6736(03)13637-9"},{"key":"1462_CR37","doi-asserted-by":"publisher","unstructured":"Milisav I, Ribari\u010d S, Poljsak B. Antioxidant Vitamins and Ageing. In: Harris JR, Korolchuk VI, editors. Biochem Cell Biol Ageing Part Biomed Sci. Singapore: Springer; 2018. p. 1\u201323. https:\/\/doi.org\/10.1007\/978-981-13-2835-0_1.","DOI":"10.1007\/978-981-13-2835-0_1"},{"key":"1462_CR38","doi-asserted-by":"publisher","unstructured":"Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21:363\u201383. https:\/\/doi.org\/10.1038\/s41580-020-0230-3","DOI":"10.1038\/s41580-020-0230-3"},{"key":"1462_CR39","doi-asserted-by":"publisher","unstructured":"Ungvari Z, Tarantini S, Ny\u00fal-T\u00f3th \u00c1, Kiss T, Yabluchanskiy A, Csipo T, et al. Nrf2 dysfunction and impaired cellular resilience to oxidative stressors in the aged vasculature: from increased cellular senescence to the pathogenesis of age-related vascular diseases. GeroScience. 2019;41:727\u201338. https:\/\/doi.org\/10.1007\/s11357-019-00107-w","DOI":"10.1007\/s11357-019-00107-w"},{"key":"1462_CR40","doi-asserted-by":"publisher","unstructured":"Mimura J, Itoh K. Role of Nrf2 in the pathogenesis of atherosclerosis. Free Radic Biol Med. 2015;88:221\u201332. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.06.019","DOI":"10.1016\/j.freeradbiomed.2015.06.019"},{"key":"1462_CR41","doi-asserted-by":"publisher","unstructured":"Xu X, Liu C, Bo J, Wang H, Zhang Y, Xu Y, et al. Nrf2 deficiency in myeloid cells accelerates atherosclerosis by promoting the inflammatory response and impairing efferocytosis. J Adv Res. 2026;S2090-1232(26)00005\u20136. https:\/\/doi.org\/10.1016\/j.jare.2026.01.005","DOI":"10.1016\/j.jare.2026.01.005"},{"key":"1462_CR42","doi-asserted-by":"publisher","unstructured":"Sarad K, Stefa\u0144ska M, Kraszewska I, Burda G, Szade K, B\u0142yszczuk P, et al. Endothelial Nrf2 deficiency promotes atherosclerotic lesion formation by shaping a proinflammatory niche. Life Sci. 2025;375:123725. https:\/\/doi.org\/10.1016\/j.lfs.2025.123725","DOI":"10.1016\/j.lfs.2025.123725"},{"key":"1462_CR43","doi-asserted-by":"publisher","unstructured":"Li H, Zhuang W, Xiong T, Park WS, Zhang S, Zha Y, et al. Nrf2 deficiency attenuates atherosclerosis by reducing LOX-1-mediated proliferation and migration of vascular smooth muscle cells. Atherosclerosis. 2022;347:1\u201316. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.02.025","DOI":"10.1016\/j.atherosclerosis.2022.02.025"},{"key":"1462_CR44","doi-asserted-by":"publisher","unstructured":"Gao S, Liu J. Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease. Chronic Dis Transl Med. 2017;3:89\u201394. https:\/\/doi.org\/10.1016\/j.cdtm.2017.02.008","DOI":"10.1016\/j.cdtm.2017.02.008"},{"key":"1462_CR45","doi-asserted-by":"publisher","unstructured":"Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, et al. Scavenger receptors class A-I\/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277:49982\u20138. https:\/\/doi.org\/10.1074\/jbc.M209649200","DOI":"10.1074\/jbc.M209649200"},{"key":"1462_CR46","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1172\/JCI26130","volume":"115","author":"JL Witztum","year":"2005","unstructured":"Witztum JL. You are right too! J Clin Invest. 2005;115:2072\u20135. https:\/\/doi.org\/10.1172\/JCI26130.","journal-title":"J Clin Invest"},{"key":"1462_CR47","doi-asserted-by":"publisher","unstructured":"Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73\u20137. https:\/\/doi.org\/10.1038\/386073a0","DOI":"10.1038\/386073a0"},{"key":"1462_CR48","doi-asserted-by":"publisher","unstructured":"Akhmedov A, Sawamura T, Chen C-H, Kraler S, Vdovenko D, L\u00fcscher TF. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. Eur Heart J. 2021;42:1797\u2013807. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa770","DOI":"10.1093\/eurheartj\/ehaa770"},{"key":"1462_CR49","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1152\/physrev.00047.2003","volume":"84","author":"R Stocker","year":"2004","unstructured":"Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381\u2013478. https:\/\/doi.org\/10.1152\/physrev.00047.2003.","journal-title":"Physiol Rev"},{"key":"1462_CR50","doi-asserted-by":"publisher","unstructured":"N\u00e8gre-Salvayre A, Aug\u00e9 N, Camar\u00e9 C, Bacchetti T, Ferretti G, Salvayre R. Dual signaling evoked by oxidized LDLs in vascular cells. Free Radic Biol Med. 2017;106:118\u201333. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.02.006","DOI":"10.1016\/j.freeradbiomed.2017.02.006"},{"key":"1462_CR51","doi-asserted-by":"publisher","unstructured":"Orekhov AN. We Must Abandon the Myth: Oxidized Low-density Lipoprotein is not a Lipoprotein that Plays a Key Role in Atherogenesis. Curr Med Chem. 2025;32:2899\u2013914. https:\/\/doi.org\/10.2174\/0109298673301236240311113807","DOI":"10.2174\/0109298673301236240311113807"},{"key":"1462_CR52","doi-asserted-by":"publisher","unstructured":"Tertov VV, Kaplun VV, Sobenin IA, Orekhov AN. Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification. Atherosclerosis. 1998;138:183\u201395. https:\/\/doi.org\/10.1016\/s0021-9150(98)00023-9","DOI":"10.1016\/s0021-9150(98)00023-9"},{"key":"1462_CR53","doi-asserted-by":"publisher","unstructured":"Lu J, Yang J-H, Burns AR, Chen H-H, Tang D, Walterscheid JP, et al. Mediation of Electronegative Low-Density Lipoprotein Signaling by LOX-1. Circ Res. American Heart Association; 2009;104:619\u201327. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.190116","DOI":"10.1161\/CIRCRESAHA.108.190116"},{"key":"1462_CR54","doi-asserted-by":"publisher","unstructured":"Ke L-Y, Engler DA, Lu J, Matsunami RK, Chan H-C, Wang G-J, et al. Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein. Pure Appl Chem Chim Pure Appl. 2011;83. https:\/\/doi.org\/10.1351\/PAC-CON-10-12-07","DOI":"10.1351\/PAC-CON-10-12-07"},{"key":"1462_CR55","doi-asserted-by":"publisher","unstructured":"Yang T-C, Chang P-Y, Lu S-C. L5-LDL from ST-elevation myocardial infarction patients induces IL-1\u03b2 production via LOX-1 and NLRP3 inflammasome activation in macrophages. Am J Physiol Heart Circ Physiol. 2017;312:H265\u201374. https:\/\/doi.org\/10.1152\/ajpheart.00509.2016","DOI":"10.1152\/ajpheart.00509.2016"},{"key":"1462_CR56","doi-asserted-by":"publisher","unstructured":"Stancel N, Chen C-C, Ke L-Y, Chu C-S, Lu J, Sawamura T, et al. Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis. Clin Chem. 2016;62:320\u20137. https:\/\/doi.org\/10.1373\/clinchem.2015.243923","DOI":"10.1373\/clinchem.2015.243923"},{"key":"1462_CR57","doi-asserted-by":"publisher","unstructured":"Kattoor AJ, Goel A, Mehta JL. LOX-1: Regulation, Signaling and Its Role in Atherosclerosis. Antioxidants. Basel, Switzerland; 2019;8:218. https:\/\/doi.org\/10.3390\/antiox8070218","DOI":"10.3390\/antiox8070218"},{"key":"1462_CR58","doi-asserted-by":"publisher","unstructured":"Chen J, Mehta JL, Haider N, Zhang X, Narula J, Li D. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res. 2004;94:370\u20136. https:\/\/doi.org\/10.1161\/01.RES.0000113782.07824.BE","DOI":"10.1161\/01.RES.0000113782.07824.BE"},{"key":"1462_CR59","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.atherosclerosis.2010.10.044","volume":"214","author":"S Ryoo","year":"2011","unstructured":"Ryoo S, Bhunia A, Chang F, Shoukas A, Berkowitz DE, Romer LH. OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis. 2011;214:279\u201387. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.10.044.","journal-title":"Atherosclerosis"},{"key":"1462_CR60","doi-asserted-by":"publisher","unstructured":"Spescha RD, Glanzmann M, Simic B, Witassek F, Keller S, Akhmedov A, et al. Adaptor protein p66(Shc) mediates hypertension-associated, cyclic stretch-dependent, endothelial damage. Hypertension. Dallas, Tex. : 1979; 2014;64:347\u201353. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02129","DOI":"10.1161\/HYPERTENSIONAHA.113.02129"},{"key":"1462_CR61","doi-asserted-by":"publisher","unstructured":"Schaeffer DF, Riazy M, Parhar KS, Chen JH, Duronio V, Sawamura T, et al. LOX-1 augments oxLDL uptake by lysoPC-stimulated murine macrophages but is not required for oxLDL clearance from plasma. J Lipid Res. 2009;50:1676\u201384. https:\/\/doi.org\/10.1194\/jlr.M900167-JLR200","DOI":"10.1194\/jlr.M900167-JLR200"},{"key":"1462_CR62","doi-asserted-by":"publisher","unstructured":"Dmitrieva AA, Mogilenko DA, Larionova EE, Nekrasova EV, Churakov GA, Orlov SV. The LOX-1 scavenger receptor plays a central role in multiple positive feedback loops driving the escalation of oxLDL uptake by macrophages. FEBS Lett. 2026;600:669\u201379. https:\/\/doi.org\/10.1002\/1873-3468.70282","DOI":"10.1002\/1873-3468.70282"},{"key":"1462_CR63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cardiores.2005.08.013","volume":"69","author":"J Hinagata","year":"2006","unstructured":"Hinagata J, Kakutani M, Fujii T, Naruko T, Inoue N, Fujita Y, et al. Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. Cardiovasc Res. 2006;69:263\u201371. https:\/\/doi.org\/10.1016\/j.cardiores.2005.08.013.","journal-title":"Cardiovasc Res"},{"key":"1462_CR64","doi-asserted-by":"publisher","unstructured":"Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K, et al. Oxidized LDL modulates Bax\/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:955\u201360. https:\/\/doi.org\/10.1161\/01.atv.21.6.955","DOI":"10.1161\/01.atv.21.6.955"},{"key":"1462_CR65","doi-asserted-by":"publisher","unstructured":"Ishino S, Mukai T, Kume N, Asano D, Ogawa M, Kuge Y, et al. Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability\u2013analysis in hypercholesterolemic rabbits. Atherosclerosis. 2007;195:48\u201356. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.11.031","DOI":"10.1016\/j.atherosclerosis.2006.11.031"},{"key":"1462_CR66","doi-asserted-by":"publisher","unstructured":"Barreto J, Karathanasis SK, Remaley A, Sposito AC. The role of LOX-1 as a cardiovascular risk predictor: Mechanistic insight and potential clinical use. Arterioscler Thromb Vasc Biol. 2021;41:153\u201366. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315421","DOI":"10.1161\/ATVBAHA.120.315421"},{"key":"1462_CR67","doi-asserted-by":"publisher","unstructured":"Kraler S, Wenzl FA, Georgiopoulos G, Obeid S, Liberale L, von Eckardstein A, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. Eur Heart J. 2022;43:1849\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehac143","DOI":"10.1093\/eurheartj\/ehac143"},{"key":"1462_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2025-326315","author":"A Schiopu","year":"2025","unstructured":"Schiopu A, Svedlund S, Narasimhan G, Juin Loong B, Yndigegn T, Varma V, et al. Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. Heart. 2025. https:\/\/doi.org\/10.1136\/heartjnl-2025-326315.","journal-title":"Heart"},{"key":"1462_CR69","doi-asserted-by":"publisher","unstructured":"Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Circ Res. 2018;122:1722\u201340. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311362","DOI":"10.1161\/CIRCRESAHA.118.311362"},{"key":"1462_CR70","doi-asserted-by":"publisher","unstructured":"Takahashi M. NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc Res. 2022;118:372\u201385. https:\/\/doi.org\/10.1093\/cvr\/cvab010","DOI":"10.1093\/cvr\/cvab010"},{"key":"1462_CR71","doi-asserted-by":"publisher","unstructured":"Mo B, Ding Y, Ji Q. NLRP3 inflammasome in cardiovascular diseases: an update. Front Immunol. 2025;16:1550226. https:\/\/doi.org\/10.3389\/fimmu.2025.1550226","DOI":"10.3389\/fimmu.2025.1550226"},{"key":"1462_CR72","doi-asserted-by":"publisher","unstructured":"Rajam\u00e4ki K, Lappalainen J, O\u00f6rni K, V\u00e4lim\u00e4ki E, Matikainen S, Kovanen PT, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PloS One. 2010;5:e11765. https:\/\/doi.org\/10.1371\/journal.pone.0011765","DOI":"10.1371\/journal.pone.0011765"},{"key":"1462_CR73","doi-asserted-by":"publisher","unstructured":"Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357\u201361. https:\/\/doi.org\/10.1038\/nature08938","DOI":"10.1038\/nature08938"},{"key":"1462_CR74","doi-asserted-by":"publisher","unstructured":"Tall AR, Bornfeldt KE. Inflammasomes and Atherosclerosis: a Mixed Picture. Circ Res. 2023;132:1505\u201320. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.321637","DOI":"10.1161\/CIRCRESAHA.123.321637"},{"key":"1462_CR75","doi-asserted-by":"publisher","unstructured":"Tall AR, Westerterp M. Inflammasomes, neutrophil extracellular traps, and cholesterol. J Lipid Res. 2019;60:721\u20137. https:\/\/doi.org\/10.1194\/jlr.S091280","DOI":"10.1194\/jlr.S091280"},{"key":"1462_CR76","doi-asserted-by":"publisher","unstructured":"Xian H, Watari K, Sanchez-Lopez E, Offenberger J, Onyuru J, Sampath H, et al. Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. Immunity. 2022;55:1370\u20131385.e8. https:\/\/doi.org\/10.1016\/j.immuni.2022.06.007","DOI":"10.1016\/j.immuni.2022.06.007"},{"key":"1462_CR77","doi-asserted-by":"publisher","unstructured":"Tumurkhuu G, Shimada K, Dagvadorj J, Crother TR, Zhang W, Luthringer D, et al. Ogg1-Dependent DNA Repair Regulates NLRP3 Inflammasome and Prevents Atherosclerosis. Circ Res. 2016;119:e76-90. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308362","DOI":"10.1161\/CIRCRESAHA.116.308362"},{"key":"1462_CR78","doi-asserted-by":"publisher","unstructured":"Dai Y, Cao Y, Zhang Z, Vallurupalli S, Mehta JL. Xanthine Oxidase Induces Foam Cell Formation through LOX-1 and NLRP3 Activation. Cardiovasc Drugs Ther. 2017;31:19\u201327. https:\/\/doi.org\/10.1007\/s10557-016-6706-x","DOI":"10.1007\/s10557-016-6706-x"},{"key":"1462_CR79","doi-asserted-by":"publisher","unstructured":"Liu Q, Shi Y, Qin L. Targeting pyroptosis in atherosclerosis: emerging pharmacologic strategies and natural compound-based therapeutics-a narrative review. Int J Clin Pharm. 2026;48:67\u201379. https:\/\/doi.org\/10.1007\/s11096-025-02065-0","DOI":"10.1007\/s11096-025-02065-0"},{"key":"1462_CR80","doi-asserted-by":"publisher","unstructured":"Yarovinsky TO, Su M, Chen C, Xiang Y, Tang WH, Hwa J. Pyroptosis in cardiovascular diseases: Pumping gasdermin on the fire. Semin Immunol. 2023;69:101809. https:\/\/doi.org\/10.1016\/j.smim.2023.101809","DOI":"10.1016\/j.smim.2023.101809"},{"key":"1462_CR81","doi-asserted-by":"publisher","unstructured":"Liu X, Luo P, Zhang W, Zhang S, Yang S, Hong F. Roles of pyroptosis in atherosclerosis pathogenesis. Biomed Pharmacother Biomedecine Pharmacother. 2023;166:115369. https:\/\/doi.org\/10.1016\/j.biopha.2023.115369","DOI":"10.1016\/j.biopha.2023.115369"},{"key":"1462_CR82","doi-asserted-by":"publisher","unstructured":"Jiang M, Sun X, Liu S, Tang Y, Shi Y, Bai Y, et al. Caspase-11-Gasdermin D-Mediated Pyroptosis Is Involved in the Pathogenesis of Atherosclerosis. Front Pharmacol. 2021;12:657486. https:\/\/doi.org\/10.3389\/fphar.2021.657486","DOI":"10.3389\/fphar.2021.657486"},{"key":"1462_CR83","doi-asserted-by":"publisher","unstructured":"Wei Y, Lan B, Zheng T, Yang L, Zhang X, Cheng L, et al. GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis. Nat Commun. 2023;14:929. https:\/\/doi.org\/10.1038\/s41467-023-36614-w","DOI":"10.1038\/s41467-023-36614-w"},{"key":"1462_CR84","doi-asserted-by":"publisher","unstructured":"Hernando-Redondo J, Ni\u00f1o OC, Fit\u00f3 M. Atherogenic low-density lipoprotein and cardiovascular risk. Curr Opin Lipidol. 2025;36:8\u201313. https:\/\/doi.org\/10.1097\/MOL.0000000000000963","DOI":"10.1097\/MOL.0000000000000963"},{"key":"1462_CR85","doi-asserted-by":"publisher","unstructured":"Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T, et al. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. J Clin Med. 2019;8:2051. https:\/\/doi.org\/10.3390\/jcm8122051","DOI":"10.3390\/jcm8122051"},{"key":"1462_CR86","doi-asserted-by":"publisher","unstructured":"Ruscica M, Tokg\u00f6zo\u011flu L, Corsini A, Sirtori CR. PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis. 2019;288:146\u201355. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.07.015","DOI":"10.1016\/j.atherosclerosis.2019.07.015"},{"key":"1462_CR87","doi-asserted-by":"publisher","unstructured":"Levstek T, Podkraj\u0161ek N, Rehberger Likozar A, \u0160ebe\u0161tjen M, Trebu\u0161ak Podkraj\u0161ek K. The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels. J Cardiovasc Dev Dis. 2022;9:127. https:\/\/doi.org\/10.3390\/jcdd9050127","DOI":"10.3390\/jcdd9050127"},{"key":"1462_CR88","doi-asserted-by":"publisher","unstructured":"Sack MN, Fyhrquist FY, Saijonmaa OJ, Fuster V, Kovacic JC. Basic Biology of Oxidative Stress and the Cardiovascular System: Part 1 of a 3-Part Series. J Am Coll Cardiol. 2017;70:196\u2013211. https:\/\/doi.org\/10.1016\/j.jacc.2017.05.034","DOI":"10.1016\/j.jacc.2017.05.034"},{"key":"1462_CR89","doi-asserted-by":"publisher","unstructured":"Ungvari Z, Tarantini S, Sorond F, Merkely B, Csiszar A. Mechanisms of Vascular Aging, A Geroscience Perspective: JACC Focus Seminar. J Am Coll Cardiol. 2020;75:931\u201341. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.061","DOI":"10.1016\/j.jacc.2019.11.061"},{"key":"1462_CR90","doi-asserted-by":"publisher","unstructured":"Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res. 2012;111:245\u201359. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.261388","DOI":"10.1161\/CIRCRESAHA.111.261388"},{"key":"1462_CR91","doi-asserted-by":"publisher","unstructured":"Zanders L, Arifaj D, Wagner JUG, Dimmeler S. Cellular Senescence, Inflammaging and Cardiovascular Disease. Immunol Rev. 2026;337:e70084. https:\/\/doi.org\/10.1111\/imr.70084","DOI":"10.1111\/imr.70084"},{"key":"1462_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020964","volume":"6","author":"M Khaidakov","year":"2011","unstructured":"Khaidakov M, Wang X, Mehta JL. Potential involvement of LOX-1 in functional consequences of endothelial senescence. PLoS One. 2011;6:e20964. https:\/\/doi.org\/10.1371\/journal.pone.0020964.","journal-title":"PLoS One"},{"key":"1462_CR93","doi-asserted-by":"publisher","unstructured":"Mir HA, Ali R, Mushtaq U, Khanday FA. Structure-functional implications of longevity protein p66Shc in health and disease. Ageing Res Rev. 2020;63:101139. https:\/\/doi.org\/10.1016\/j.arr.2020.101139","DOI":"10.1016\/j.arr.2020.101139"},{"key":"1462_CR94","doi-asserted-by":"publisher","unstructured":"Paneni F, Diaz Ca\u00f1estro C, Libby P, L\u00fcscher TF, Camici GG. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. J Am Coll Cardiol. 2017;69:1952\u201367. https:\/\/doi.org\/10.1016\/j.jacc.2017.01.064","DOI":"10.1016\/j.jacc.2017.01.064"},{"key":"1462_CR95","doi-asserted-by":"publisher","unstructured":"Yin Y, Zhou Z, Liu W, Chang Q, Sun G, Dai Y. Vascular endothelial cells senescence is associated with NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation via reactive oxygen species (ROS)\/thioredoxin-interacting protein (TXNIP) pathway. Int J Biochem Cell Biol. 2017;84:22\u201334. https:\/\/doi.org\/10.1016\/j.biocel.2017.01.001","DOI":"10.1016\/j.biocel.2017.01.001"},{"key":"1462_CR96","doi-asserted-by":"publisher","unstructured":"Gardner SE, Humphry M, Bennett MR, Clarke MCH. Senescent Vascular Smooth Muscle Cells Drive Inflammation Through an Interleukin-1\u03b1-Dependent Senescence-Associated Secretory Phenotype. Arterioscler Thromb Vasc Biol. 2015;35:1963\u201374. https:\/\/doi.org\/10.1161\/ATVBAHA.115.305896","DOI":"10.1161\/ATVBAHA.115.305896"},{"key":"1462_CR97","doi-asserted-by":"publisher","unstructured":"Lin J, Chen S, Tan D, Yang X, Guo W, Cang P, et al. Long-term Senolytic Treatment Prevents Endothelial Dysfunction in Arterial Aging. Aging Dis. 2025; https:\/\/doi.org\/10.14336\/AD.2025.0976","DOI":"10.14336\/AD.2025.0976"},{"key":"1462_CR98","doi-asserted-by":"publisher","unstructured":"Atlante S, Gottardi Zamperla M, Cis L, Farsetti A, Gaetano C. Senolytic therapies for cardiovascular aging: tackling fibrosis and metabolic dysfunction. Eur J Intern Med. 2025;140:106413. https:\/\/doi.org\/10.1016\/j.ejim.2025.07.009","DOI":"10.1016\/j.ejim.2025.07.009"},{"key":"1462_CR99","doi-asserted-by":"publisher","unstructured":"Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2025;S0735-1097(25)07555-2. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.047","DOI":"10.1016\/j.jacc.2025.08.047"},{"key":"1462_CR100","doi-asserted-by":"publisher","unstructured":"Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. London, England; 2018;391:319\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(17)32814-3","DOI":"10.1016\/S0140-6736(17)32814-3"},{"key":"1462_CR101","doi-asserted-by":"publisher","unstructured":"Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol. 2014;63:2491\u2013502. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.054","DOI":"10.1016\/j.jacc.2014.01.054"},{"key":"1462_CR102","doi-asserted-by":"publisher","unstructured":"Margaritis M, Sanna F, Antoniades C. Statins and oxidative stress in the cardiovascular system. Curr Pharm Des. 2017; https:\/\/doi.org\/10.2174\/1381612823666170926130338","DOI":"10.2174\/1381612823666170926130338"},{"key":"1462_CR103","doi-asserted-by":"publisher","unstructured":"Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014;20:1198\u2013215. https:\/\/doi.org\/10.1089\/ars.2013.5430","DOI":"10.1089\/ars.2013.5430"},{"key":"1462_CR104","doi-asserted-by":"publisher","unstructured":"Mehta JL, Chen J, Yu F, Li DY. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res. 2004;64:243\u20139. https:\/\/doi.org\/10.1016\/j.cardiores.2004.07.002","DOI":"10.1016\/j.cardiores.2004.07.002"},{"key":"1462_CR105","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2005.08.030","volume":"187","author":"N Kobayashi","year":"2006","unstructured":"Kobayashi N, Honda T, Yoshida K, Nakano S, Ohno T, Tsubokou Y, et al. Critical role of bradykinin-eNOS and oxidative stress-LOX-1 pathway in cardiovascular remodeling under chronic angiotensin-converting enzyme inhibition. Atherosclerosis. 2006;187:92\u2013100. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2005.08.030.","journal-title":"Atherosclerosis"},{"key":"1462_CR106","doi-asserted-by":"publisher","unstructured":"Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. Dallas, Tex. : 1979; 2006;48:677\u201384. https:\/\/doi.org\/10.1161\/01.HYP.0000239207.82326.29","DOI":"10.1161\/01.HYP.0000239207.82326.29"},{"key":"1462_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108053","volume":"236","author":"S Toldo","year":"2022","unstructured":"Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther. 2022;236:108053. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108053.","journal-title":"Pharmacol Ther"},{"key":"1462_CR108","doi-asserted-by":"publisher","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563","DOI":"10.1056\/NEJMoa2307563"},{"key":"1462_CR109","doi-asserted-by":"publisher","unstructured":"Wang T, Ding J, Cheng X, Yang Q, Hu P. Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease. Front Pharmacol. 2024;15:1396656. https:\/\/doi.org\/10.3389\/fphar.2024.1396656","DOI":"10.3389\/fphar.2024.1396656"},{"key":"1462_CR110","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","volume":"326","author":"B Park","year":"2024","unstructured":"Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, et al. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol. 2024;326:H1159-76. https:\/\/doi.org\/10.1152\/ajpheart.00574.2023.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1462_CR111","doi-asserted-by":"publisher","unstructured":"Kassab MB, Khraishah H, Thrapp A, Abohashem SM, Vijay A, Rentz T, et al. Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity. Eur Heart J. 2026;ehag060. https:\/\/doi.org\/10.1093\/eurheartj\/ehag060","DOI":"10.1093\/eurheartj\/ehag060"},{"key":"1462_CR112","doi-asserted-by":"publisher","unstructured":"Kim SR, Lee S-G, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11:2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6","DOI":"10.1038\/s41467-020-15983-6"},{"key":"1462_CR113","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022;386:2024\u201334. https:\/\/doi.org\/10.1056\/NEJMra2115011.","journal-title":"N Engl J Med"},{"key":"1462_CR114","doi-asserted-by":"publisher","unstructured":"Li X, Preckel B, Hermanides J, Hollmann MW, Zuurbier CJ, Weber NC. Amelioration of endothelial dysfunction by sodium glucose co-transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection. Br J Pharmacol. 2022;179:4047\u201362. https:\/\/doi.org\/10.1111\/bph.15850","DOI":"10.1111\/bph.15850"},{"key":"1462_CR115","doi-asserted-by":"publisher","unstructured":"Zeng W, Wu D, Sun Y, Suo Y, Yu Q, Zeng M, et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages. Sci Rep. 2021;11:19305. https:\/\/doi.org\/10.1038\/s41598-021-98437-3","DOI":"10.1038\/s41598-021-98437-3"},{"key":"1462_CR116","doi-asserted-by":"publisher","unstructured":"Zhao TX, Mallat Z. Targeting the Immune System in Atherosclerosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:1691\u2013706. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.083","DOI":"10.1016\/j.jacc.2018.12.083"},{"key":"1462_CR117","doi-asserted-by":"publisher","unstructured":"Bai F, Wang D, Wu Y. Dapansutrile in multidisciplinary therapeutic applications: mechanisms and clinical perspectives. Front Pharmacol [Internet]. Frontiers; 2025 [cited 2026 May 14];16. https:\/\/doi.org\/10.3389\/fphar.2025.1731165","DOI":"10.3389\/fphar.2025.1731165"},{"key":"1462_CR118","doi-asserted-by":"publisher","unstructured":"Ridker PM, Baeres FMM, Hveplund A, Engelmann MMD, Hovingh GK, Lincoff AM, et al. Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction. JAMA Cardiol. 2026;11:89\u201397. https:\/\/doi.org\/10.1001\/jamacardio.2025.4491","DOI":"10.1001\/jamacardio.2025.4491"},{"key":"1462_CR119","doi-asserted-by":"publisher","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. London, England; 2021;397:2060\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(21)00520-1","DOI":"10.1016\/S0140-6736(21)00520-1"},{"key":"1462_CR120","doi-asserted-by":"publisher","unstructured":"Mercer JR, Yu E, Figg N, Cheng K-K, Prime TA, Griffin JL, et al. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+\/-\/ApoE-\/- mice. Free Radic Biol Med. 2012;52:841\u20139. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.11.026","DOI":"10.1016\/j.freeradbiomed.2011.11.026"},{"key":"1462_CR121","doi-asserted-by":"publisher","unstructured":"Rossman MJ, Santos-Parker JR, Steward CAC, Bispham NZ, Cuevas LM, Rosenberg HL, et al. Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults. Hypertension. Dallas, Tex. : 1979; 2018;71:1056\u201363. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10787","DOI":"10.1161\/HYPERTENSIONAHA.117.10787"},{"key":"1462_CR122","doi-asserted-by":"publisher","unstructured":"Murray KO, Ludwig KR, Darvish S, Coppock ME, Seals DR, Rossman MJ. Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress. Am J Physiol Heart Circ Physiol. 2023;325:H187\u201394. https:\/\/doi.org\/10.1152\/ajpheart.00270.2023","DOI":"10.1152\/ajpheart.00270.2023"},{"key":"1462_CR123","doi-asserted-by":"publisher","unstructured":"Jean-Gilles M, Gencer B. Therapeutic advances in the Lp(a) battle: what do we know and what are the most awaited novelties in the field? Curr Opin Lipidol. 2025;36:130\u20137. https:\/\/doi.org\/10.1097\/MOL.0000000000000981","DOI":"10.1097\/MOL.0000000000000981"},{"key":"1462_CR124","doi-asserted-by":"publisher","unstructured":"Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk? Pharmaceuticals. Basel, Switzerland; 2025;18:753. https:\/\/doi.org\/10.3390\/ph18050753","DOI":"10.3390\/ph18050753"},{"key":"1462_CR125","doi-asserted-by":"publisher","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet. London, England; 2024;404:1255\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(24)01308-4","DOI":"10.1016\/S0140-6736(24)01308-4"},{"key":"1462_CR126","unstructured":"Abstract 17013: CTX320: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces Lipoprotein (a) Levels in Non-Human Primates After a Single Dose. Circulation [Internet]. [cited 2026 May 14]; https:\/\/www.ahajournals.org\/doi\/10.1161\/circ.148.suppl_1.17013. Accessed 14 May 2026"},{"key":"1462_CR127","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/eurheartj\/ehaf174","volume":"46","author":"M Samuel","year":"2025","unstructured":"Samuel M, Berry C, Dub\u00e9 M-P, Koenig W, L\u00f3pez-Send\u00f3n J, Maggioni AP, et al. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J. 2025;46:2552\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf174.","journal-title":"Eur Heart J"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01462-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01462-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01462-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:25:09Z","timestamp":1790659509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01462-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01462-8","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No animal or human subjects by the authors were used in this study.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}